Verax Biomedical Renews Commercialization Agreement with Fresenius Kabi

 

MARLBOROUGH, Mass.–Verax Biomedical today announced it has renewed its exclusive commercialization agreement with Fresenius Kabi USA (www.fresenius-kabi.us), continuing Verax’s leadership position in platelet safety for transfusion medicine.

The agreement permits Fresenius Kabi USA to market, sell and distribute Verax’s unique PanGenera® Detection (PGD) test, a rapid in vitro diagnostic test used to detect bacterial contaminants in donated platelets. The Verax Platelet PGD® test is the only rapid test on the market cleared by the FDA for all commonly available U.S. platelet types. The FDA also now permits platelet supplies to be extended to seven (7) days, instead of the previously permitted five (5) days, for apheresis platelets in plasma that have been safety tested using the Verax PGD® test.

Subscribe to get the latest news